Edwards Lifesciences Corporation
Financials
Valuation Metrics
Edwards Lifesciences Corporation's Market Cap is $50.82B. At end of 2025 it was $49.48B. Ranked #314 of 3,121 in US market (top 10%), #230 of 1,658 on NYSE (top 14%), #17 of 205 in Health Care Equipment & Services (top 8%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $50.82B | US#314/3,121 Sec#17/205 |
| Revenue | $6.51B | US#751/3,121 Sec#41/205 |
| Net Income | $1.00B | US#543/3,121 Sec#29/205 |
| Total Assets | $13.87B | US#807/3,121 Sec#38/205 |
| Net Assets | $10.62B | US#405/3,121 Sec#23/205 |
| Employees | 16,000 | US#643/3,121 Sec#48/205 |
| Value | ||
| P/E | 50.57x | US#1,922/3,121 Sec#101/205 |
| P/B | 4.79x | US#2,188/3,121 Sec#132/205 |
| P/S | 7.80x | US#2,591/3,121 Sec#172/205 |
| EV/EBITDA | 31.57x | US#2,235/3,121 Sec#122/205 |
| FCF Yield | 2.82% | US#1,877/3,121 Sec#109/205 |
| Profitability | ||
| ROE | 9.46% | US#1,427/3,121 Sec#69/205 |
| ROA | 7.25% | US#749/3,121 Sec#44/205 |
| Op. Margin | 28.09% | US#593/3,121 Sec#14/205 |
| Revenue Growth | 14.55% | US#940/3,121 Sec#64/205 |
| Earnings Growth | -75.75% | US#1,830/3,121 Sec#97/205 |
| Financial Health | ||
| Debt Ratio | 29.59% | US#328/3,121 Sec#33/205 |
| Total Debt | $704M | US#1,721/3,121 Sec#95/205 |
| FCF | $1.43B | US#468/3,121 Sec#30/205 |
| Cash | $2.91B | US#309/3,121 Sec#16/205 |
| Current Ratio | 4.52x | US#530/3,121 Sec#47/205 |
| Net Debt/EBITDA | -1.43x | US#234/3,121 Sec#16/205 |
| Performance | ||
| 1Y Return | 18.38% | US#1,244/3,121 Sec#94/205 |
| 1M Return | -4.36% | US#1,381/3,121 Sec#119/205 |
| From 52W High | -8.34% | US#581/3,121 Sec#58/205 |
| 1Y MDD | -13.19% | US#198/3,121 Sec#3/205 |
| Trading | ||
| Volume | 2,477,425 shares | US#621/3,121 Sec#33/205 |
| Trading Value | $218M | US#371/3,121 Sec#27/205 |
| Per Share | ||
| EPS | $1.75 | US#1,416/3,121 Sec#73/205 |
| BPS | $18.44 | US#1,319/3,121 Sec#73/205 |
Company Info
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.